EDA Egypt Pharmaceutical Import: A Complete 2026 Process Guide for UK Exporters

Egypt is the largest pharmaceutical market in North Africa and the most populous Arab country, with a population now in excess of 110 million and a healthcare system in the middle of one of the most ambitious reform programmes in the region. For UK pharmaceutical exporters operating under MHRA Wholesale Dealer Authorisation, Egypt represents a significant and growing demand base for specialty oncology, rare disease, biologic, paediatric, and named patient supply, alongside steady tender and shortage volumes for both the public hospital network and private sector providers.

The regulatory authority that controls every aspect of pharmaceutical import into Egypt is the Egyptian Drug Authority, the EDA. Established in 2019 as an independent national regulator, it took over the medicines functions of the former Central Administration for Pharmaceutical Affairs and is now the single contact point for marketing authorisation, import licensing, GMP inspection, pharmacovigilance and post-market surveillance. Understanding how the EDA operates, and how its requirements interact with hospital procurement, named patient pathways, customs procedures and the rolling Universal Health Insurance reform, is the foundation of any reliable UK to Egypt pharmaceutical supply operation.

This guide covers the full process for UK exporters in 2026: market context, EDA structure, the principal routes to market, documentation, registration timelines, pricing controls, currency considerations, customs and cold chain handling at Cairo and El Adabiya, the institutional procurement landscape under MOHP and the new UHI system, common pitfalls, and how Euro Biom supports UK to Egypt supply.

Egypt Pharma Market Context in 2026

Egypt is the largest healthcare consumer in the Arab world by population. The country's pharmaceutical market is estimated to exceed USD 8 billion annually, with double-digit local currency growth driven by a young, expanding population, the rolling Universal Health Insurance reform, and increasing investment in cancer care, cardiology, and rare-disease centres of excellence. Egypt also hosts the largest concentration of pharmaceutical manufacturing capacity in Africa, but is structurally import-dependent for biologics, advanced oncology therapies, modern insulins, niche paediatric formulations, orphan drugs and a long tail of specialty medicines that local manufacturing cannot economically replicate.

The Vision 2030 healthcare reform programme, articulated through the Universal Health Insurance Law of 2018 and being implemented governorate-by-governorate, is reshaping how medicines are paid for, procured and distributed. Port Said, Ismailia, South Sinai, Suez and Luxor were among the first governorates fully migrated to the UHI model. Cairo and Giza are scheduled to follow within the current reform window. This shift consolidates institutional purchasing power into the Universal Health Insurance Authority and the General Authority for Healthcare, restructuring how UK suppliers and their Egyptian partners need to position registered, named patient and tender supply.

Alongside the public sector, Egypt has a substantial private hospital industry concentrated in Cairo, Alexandria and the Greater Cairo medical corridor, an active medical tourism segment, and a strong NGO and donor-funded supply channel covering refugee health, hepatitis C eradication, and the United Nations agencies based in Cairo. Each of these channels has different procurement rhythms, different documentation expectations and different tolerance for unregistered, named patient and shortage supply.

The EDA: How the Egyptian Drug Authority Is Structured

The Egyptian Drug Authority was established by Presidential Decree 777 of 2019 as an autonomous regulatory body reporting to the Prime Minister. It absorbed and reorganised the previous Central Administration for Pharmaceutical Affairs, known as CAPA, that had sat within the Ministry of Health and Population for decades. The EDA is now the sole regulator for human medicines, biologicals, vaccines, blood products, controlled drugs and pharmacy practice across Egypt.

Internally, the EDA is organised into several directorates that any UK exporter or their Egyptian partner will encounter during the import process:

• Central Administration for Pharmaceutical Products, handling new and renewal marketing authorisation applications for finished products
• Central Administration for Biological Products, covering vaccines, biosimilars, blood products and advanced therapies
• Central Administration for Inspection, conducting GMP inspections of foreign manufacturing sites and Egyptian distributors
• Central Administration for Operations, issuing the shipment-specific import permits that customs requires for clearance
• Pricing Committee, setting and adjusting the ex-factory and retail price of every registered medicine
• Special Cases Committee, reviewing applications for compassionate use and named patient supply of unregistered medicines
• Pharmacovigilance Centre, the national focal point for safety reporting and signal detection

UK exporters do not normally interact with the EDA directly. The Egyptian regulatory model places the in-country burden on a registered scientific office or a licensed importer, which is the legal entity that holds the marketing authorisation and submits all dossiers, variations, pharmacovigilance reports and import permit applications on behalf of the foreign manufacturer or marketing authorisation holder.

Routes to the Egyptian Market

There are four practical routes for a UK pharmaceutical product to reach an Egyptian patient. Each has its own documentation, timelines and commercial structure, and each suits a different class of product.

Route 1: Full EDA registration

This is the standard pathway for products intended for routine, repeat commercial supply. A UK manufacturer or marketing authorisation holder appoints a local scientific office or licensed importer, and that local entity submits a full Common Technical Document dossier through the EDA's electronic submission system. Once the marketing authorisation is granted and the price is approved, the product can be imported through repeat shipment-specific import permits, distributed across Egypt, and tendered into the public sector procurement programme. EDA registration is a serious investment of time and documentation, but it is the only route that supports volume supply.

Route 2: Named patient through the Special Cases Committee

For products that are not registered with the EDA but are clinically required for a specific identified Egyptian patient, the Special Cases Committee operates Egypt's compassionate use and named patient pathway. A treating physician confirms in writing that no licensed alternative is available locally, the hospital's pharmacy and ethics committee endorses the request, and a licensed importer files the application with the EDA. The supplier documentation, in particular the Certificate of Pharmaceutical Product issued by the MHRA, the manufacturer's GMP certificate and the batch documentation, is required as part of the application. This is the principal route for a UK MHRA-licensed wholesaler supporting Egyptian oncology, rare disease, paediatric and advanced therapy supply, and it sits closely alongside the UK named patient supply framework we operate domestically. For an end-to-end view of how named patient supply works in the UK, our complete named patient guide sets out the prescriber and wholesaler obligations.

Route 3: Donor and UN procurement

Egypt is host to a substantial humanitarian and donor footprint, with UNHCR, UNICEF, WHO Egypt Country Office, the Global Fund and a number of bilateral donor programmes operating either in country or with Egypt as a regional logistics hub. Donor-funded medicines may be procured through WHO prequalification, the UN procurement systems, or specialised humanitarian wholesalers, with EDA accepting these supply chains under the public sector exception where the medicines are channelled to specific MOHP or NGO programmes. UK exporters can serve this channel both directly and through the United Nations Global Marketplace as a registered supplier.

Route 4: Direct hospital and licensed importer supply

University teaching hospitals, large private hospital groups and licensed importers can purchase registered medicines directly from a UK MHRA-licensed wholesaler under shipment-specific import permits, without depending on a domestic distributor. This is the pattern we see most often for oncology, biologics, anaesthesia, intensive care and shortage replenishment, and it sits alongside our broader tender and government supply work. The product must either be EDA-registered, with the local importer holding the import permit, or be imported under a Special Cases approval where it is unregistered.

Documentation Required for an Egypt Shipment

The Egyptian Drug Authority and Egyptian customs authorities expect a precise documentation package for every pharmaceutical import. Documentation gaps are the single most common cause of delays at Cairo Airport, El Adabiya port, Damietta and Alexandria. A UK MHRA-licensed wholesale dealer should be in a position to issue or compile the following on every shipment.

Arabic labelling is one of the most common reasons UK shipments are held at Egyptian customs. The EDA expects the outer carton, the patient information leaflet and, for many product categories, the primary container to carry compliant Arabic translations of the product name, the active ingredient, the strength, the dosage form, the storage instructions, the expiry date and the importer details. For named patient shipments where over-labelling is permitted, the importer's local labelling partner usually applies the Arabic over-label after customs release under EDA-approved supervision.

EDA Registration Timeline and Process

Registering a UK-manufactured pharmaceutical product with the EDA is a structured process that is broadly aligned with the World Health Organization's Common Technical Document model. The process can be broken into the following stages, which together typically span 12 to 18 months for a new molecule and 18 to 30 months for a biological or complex generic.

1. Local representation, appointment of an Egyptian scientific office or licensed importer who will file the dossier and hold the marketing authorisation
2. Pre-submission meeting, optional but increasingly used for complex products, allowing the EDA to flag dossier expectations and any likely deficiencies in advance
3. Dossier preparation, compilation of the full CTD with Egyptian-specific addenda, including the CPP, GMP certificate, Arabic labelling text and Egyptian-format product information
4. Pricing application, submitted in parallel, comparing the proposed Egyptian price to the comparator basket, evidencing the manufacturing currency and any Currency Devaluation Premium request
5. Technical review, EDA's reviewers assess the chemistry, manufacturing and controls section, the non-clinical and clinical sections, and the local addenda
6. GMP inspection, physical or desk inspection of the UK manufacturing site, mutually recognised arrangements between EDA and MHRA-equivalent authorities can sometimes substitute
7. Pricing approval, once technical review is positive, the Pricing Committee issues the approved ex-factory and retail price
8. Marketing authorisation, the EDA issues the registration certificate and adds the product to the Egyptian register
9. Initial import, the local importer files the first shipment-specific import permit application against the new registration

Fast-track pathways are available for orphan medicines, oncology innovations, paediatric-only formulations and products designated as priority by the Ministry of Health and Population. The EDA has demonstrated willingness to compress timelines significantly for products with a clear public health rationale, particularly where a product has already secured EMA, MHRA or FDA approval and where the CPP is robust.

Pricing Controls and Currency Considerations

Egypt operates one of the more interventionist pharmaceutical pricing regimes in the region. The EDA's Pricing Committee sets both the ex-factory and the retail price for every registered medicine. The methodology is based on external reference pricing across a basket of countries that includes the country of origin and a number of regional reference markets, adjusted for therapeutic class, manufacturer category and local cost factors.

Two specific features of the Egyptian pricing system materially affect UK exporters in 2026.

The first is the Currency Devaluation Premium. Following the substantial depreciation of the Egyptian Pound between 2022 and 2024, the EDA introduced a mechanism that allows selected categories of imported medicines to apply for an indexed price adjustment where the manufacturing currency, in the UK case Sterling, has substantially diverged from the Egyptian Pound. The premium is applied as a structured uplift on the ex-factory price, subject to category eligibility and Pricing Committee approval. This mechanism is particularly relevant for chronic-use medicines, where the volume base would otherwise be eroded by FX exposure.

The second is the Pricing Committee's tendency to apply downward pressure at registration time, particularly where the dossier discloses a UK list price that is significantly above the regional comparator average. UK exporters should agree foreign exchange and indexation positions contractually with their Egyptian partner before the dossier is filed, and should expect a negotiation rather than an automatic acceptance of the proposed UK-derived price.

Public sector tendering operates a further layer of price competition. The Universal Health Insurance Authority and the General Authority for Healthcare run periodic tenders that effectively re-price the registered medicine for institutional supply, often at a discount to the EDA-approved retail price. Tender pricing is commercially sensitive and should be modelled product by product against the public sector volume opportunity.

Customs, Cairo Airport and El Adabiya

Pharmaceutical imports clear Egypt through three principal entry points: Cairo International Airport for air freight, El Adabiya port at Suez and Alexandria port for sea freight, and Damietta port for selected shipments. The choice of entry point is dictated by product type, volume, urgency and cold chain requirements.

Cairo International Airport is the dominant entry for time-sensitive specialty products, named patient shipments, oncology and biologic supply, particularly anything with a 2 to 8 degrees Celsius requirement. The airport has dedicated pharmaceutical handling at terminal 2 with temperature-controlled storage, and the major freight forwarders maintain GDP-aligned ground handling. Customs processing for a fully documented pharmaceutical shipment with a valid EDA import permit is typically 24 to 72 hours, with same-day clearance available for emergency consignments where the importer has submitted advance notification.

El Adabiya, at the southern entrance to the Suez Canal, is increasingly the preferred port for bulk pharmaceutical sea freight, replacing some legacy Alexandria volumes. It offers more predictable berthing and a less congested pharmaceutical handling lane. Sea freight is the channel of choice for ambient-stable products in volume, where the longer transit time of approximately three to four weeks from UK ports is offset by lower freight cost per unit.

Alexandria continues to handle a substantial share of pharmaceutical sea freight, particularly for products destined for the Mediterranean coastal hospital network. Damietta sees a smaller share, primarily where specific manufacturer or importer arrangements direct the shipment there.

Customs delays in Egypt almost always trace back to one of the same root causes: an Arabic labelling discrepancy, a missing or incorrectly legalised commercial invoice, a Certificate of Pharmaceutical Product whose format does not align with EDA expectations, a GMP certificate that does not specifically cover the dosage form being imported, or a temperature data file with a gap that cannot be reconciled. A disciplined UK supplier prevents almost all of these by checking the documentation pack against the EDA template before dispatch.

Hospital Procurement: MOHP, UHI, GAH and the Universities

Egypt's institutional pharmaceutical buyers operate at substantial scale. Understanding which institution is procuring, under which budget, and to which standards, is essential to commercial success.

Ministry of Health and Population (MOHP)

The MOHP retains responsibility for primary healthcare, public health programmes, vaccine procurement through the Egyptian Holding Company for Biological Products and Vaccines (VACSERA), and the residual Curative Care Authority hospital network. MOHP procurement runs through periodic tenders, often denominated in Egyptian Pounds with USD reference, and is typically administered through the Unified Procurement Authority for Medical Supplies (UPA), a relatively recently established body that consolidated several legacy procurement bodies into a single tendering function for MOHP and certain affiliated hospitals.

Universal Health Insurance Authority (UHIA)

Under the rolling Universal Health Insurance reform, the UHIA is becoming the dominant payer and procurement authority for hospital medicines in the governorates that have already migrated to the UHI system. UHIA procurement uses a positive list approach combined with category tenders, and is steadily expanding to cover the population of every Egyptian governorate over the reform window through to 2032.

General Authority for Healthcare (GAH)

The GAH operates the public hospital network within UHI-active governorates. Its procurement is closely coupled to UHIA pricing decisions and the UHI positive list, and it handles the day-to-day stock management of ward-level pharmaceutical supply. UK exporters working through Egyptian partners commonly encounter the GAH at the operational delivery level, with UHIA setting the strategic procurement parameters.

University teaching hospitals

Egypt's major university teaching hospitals operate semi-autonomously and remain important institutional buyers in their own right. The most active for international pharmaceutical procurement are:

• Kasr Al Aini, Cairo University's faculty of medicine hospital, one of the oldest and largest teaching hospitals in the Arab world
• Ain Shams University Hospital, Cairo, with a strong oncology and rare disease referral profile
• Mansoura University Hospital, with the country's leading urology, hepatology and transplant centres
• Alexandria University Hospital, serving the Mediterranean coastal population
• Assiut University Hospital, the principal referral centre for Upper Egypt
• The Children's Cancer Hospital Egypt 57357, a charity-funded paediatric oncology centre with significant international purchasing
• The Egyptian Liver Research Institute and Hospital, central to the country's hepatitis C eradication programme

Each of these institutions has its own procurement department, its own tendering rhythm and its own appetite for named patient and unregistered supply. UK exporters supplying these institutions through licensed importers should expect bespoke commercial terms and bespoke documentation requirements alongside the standard EDA package.

Universal Health Insurance Rollout in 2026

The Universal Health Insurance reform, legislated under Law 2 of 2018 and rolled out in phases since 2019, is the single largest structural change in Egyptian healthcare in a generation. By the end of 2025, the UHI system was fully active in approximately one third of Egypt's 27 governorates, with the remaining governorates scheduled across a six-phase rollout plan that runs through to 2032.

For pharmaceutical procurement this has three direct consequences in 2026. First, UHIA-controlled procurement now exceeds MOHP traditional procurement by spend in the active governorates, shifting the centre of gravity for institutional pharmaceutical demand. Second, the UHI positive list, the formulary that defines which medicines are reimbursed under UHI cover, is becoming the most important market access decision for any new product entering Egypt. Third, the UHI system is creating new opportunities for outcomes-based contracting, value-based pricing and managed entry agreements that did not previously exist in the Egyptian market, with the UHIA actively piloting these mechanisms for high-cost oncology and rare disease products.

UK exporters thinking ahead about Egyptian market entry should design their dossiers, their pricing positions and their evidence packages with the UHI positive list in mind, even where the initial route to market is named patient supply. The pathway from named patient and Special Cases imports today, to UHI positive list inclusion in three to five years, is a recognisable trajectory that we now see unfolding for several specialty UK products.

Cold Chain Considerations for Egypt

Egyptian summer ambient temperatures regularly exceed 40 degrees Celsius across Cairo, Upper Egypt and the Nile Delta, with sustained heatwaves above 45 degrees Celsius now a recurring feature. Pharmaceutical cold chain integrity from London Heathrow through to a Cairo or Mansoura hospital pharmacy requires careful design.

For 2 to 8 degrees Celsius products, the standard model is qualified passive packaging or active container shipping, with full data logger coverage from the UK warehouse through to delivery acceptance. Cairo International Airport's pharmaceutical handling lane is fit for purpose, but the most common point of cold chain risk is the road segment from the airport to the hospital pharmacy or central importer warehouse, particularly during summer months and during port congestion periods. We recommend pre-cooled vehicles, ambient excursion limits agreed with the importer in advance, and a contingency plan for shipment hold at the airport's temperature-controlled storage if onward transport conditions are not safe.

For frozen biologics and advanced therapies, dry ice replenishment routines must be agreed contractually with the importer, and the UK supplier must specify the worst-case transit time the packaging is qualified for. Our guidance to Egyptian partners is to plan for at least 96 hours of qualified maintenance for any shipment routed through Cairo, allowing margin for customs delay and onward distribution. We cover the broader UK to international cold chain framework in our cold chain pharmaceutical supply guide.

Sea freight cold chain to El Adabiya or Alexandria is technically possible for 2 to 8 degrees Celsius products in qualified active reefer containers, but the operational risk profile is substantially higher than air freight, and the industry default for chilled and frozen specialty products remains air freight via Cairo.

Common Pitfalls in UK to Egypt Supply

Across the UK to Egypt pharmaceutical supply lane, the same operational issues recur often enough to deserve specific attention.

Arabic labelling rejection

The EDA's Arabic labelling expectations are precise. Translation errors, missing fields, incorrect importer details and non-compliant fonts are the leading cause of customs rejection. UK suppliers should insist on a labelling proof from the Egyptian importer before shipping any new product code, and should retain a controlled copy of each approved label revision in their documentation file.

Currency hedging gaps

The Egyptian Pound has shown substantial volatility against Sterling over the past 36 months. Without a contractual indexation clause, UK exporters bear the FX risk between order acceptance and payment receipt, and that risk has at times exceeded the entire commercial margin on a deal. Currency Devaluation Premium application, USD invoicing, FX forward cover and indexation language in the supply contract should all be agreed before the first commercial order.

Port clearance delays

Egyptian customs has been progressively modernised, but port clearance delays still occur, particularly during high-volume periods, when documentation has reconcilable but not preformat-perfect issues, and when the importer's customs broker is not specialised in pharmaceutical handling. Rail back-up plans for Cairo to Mansoura, Alexandria to Cairo and Cairo to Assiut routings can be useful contingencies, particularly for time-critical named patient shipments.

EDA Special Cases timing

Named patient and compassionate use approvals through the Special Cases Committee can take from a few days to several weeks depending on the completeness of the application and the season. UK suppliers should not commit to a delivery date before the Special Cases approval is in hand, and Egyptian partners should be encouraged to file these applications early and with supporting clinical documentation already pre-aligned with EDA expectations.

Halal certification ambiguity

For products containing gelatin, certain biologicals or specific excipient profiles, halal certification expectations vary by product category. UK exporters should confirm with the importer at the dossier stage whether halal evidence is required, and from which certification body, rather than assume that a UK-issued statement will be accepted at face value.

Hospital ethics committee timelines

For named patient supply into the university teaching hospitals, the institution's pharmacy and ethics committee timeline must be planned for in addition to the EDA Special Cases timeline. These committees often meet weekly or biweekly, and the right sequencing of clinician request, hospital approval, EDA approval and supplier dispatch is the difference between a four-week supply and a two-week supply for the same patient.

How Euro Biom Supports UK to Egypt Supply

Euro Biom is an MHRA-licensed UK pharmaceutical wholesale dealer, holding WDA(H) 59239, with our principal warehouse at Heathrow and a dedicated regional desk for Middle East and North African supply. We support UK to Egypt pharmaceutical supply across three core service lines, alongside our broader service portfolio and the wider MENA region landing page.

For named patient and unregistered medicine supply, we work directly with Egyptian licensed importers and treating hospital pharmacies to assemble the supplier-side documentation package the EDA Special Cases Committee expects. This typically includes the MHRA-issued Certificate of Pharmaceutical Product in WHO format, the manufacturer's GMP certificate, the batch-specific Certificate of Analysis, the manufacturer's batch release, the GDP chain-of-custody record, full temperature data and the legalised commercial documentation. Our clinical desk supports the Egyptian importer through the Special Cases application where supplier evidence is required.

For shortage and emergency supply, our Heathrow stockholding and our network of UK GMP manufacturers allow us to dispatch within 24 to 72 hours of confirmed enquiry for products held in active stock, with delivery into Cairo within 24 to 48 hours of dispatch. We hold active shortage cover for several Egyptian high-frequency requests, and our team in London is structured to respond same day to Egyptian-initiated enquiries during Cairo working hours.

For institutional and tender supply, we work with Egyptian licensed importers participating in MOHP, UHIA, GAH and university teaching hospital tenders, providing product availability confirmation, full pricing, full documentation and delivery commitments suitable for tender submissions. This sits alongside our broader Egypt country page and our experience supporting African hospital medicine procurement from a UK base.

Our published guidance for hospital pharmacy and procurement teams in Egypt is that the most reliable UK to Egypt supply lane is built on three principles: a UK supplier with current MHRA authorisation and discipline on the EDA documentation template, an Egyptian licensed importer with a track record of EDA submissions and Cairo customs clearance, and a written commercial framework that accommodates Egyptian pricing controls, currency volatility and Special Cases timing. Where those three are aligned, supply into Egypt from the UK is fast, predictable and operationally robust.